PREVALENCE, RISK FACTOR, MANAGEMENT AND OUTCOME OF RESISTANT HYPERTENSION: SYSTEMATIC REVIEW

Authors

  • Mohamad Azwar Aziz General Practitioner, Arjawinangun Regional General Hospital, Indonesia Author
  • Yulia Intan Kania Faculty of Medicine, Muhammadiyah University of Surakarta, Indonesia Author
  • Ilham Aziz Faculty of Medicine, Muhammadiyah University of Surakarta, Indonesia Author
  • Sibli Internal Medicine Consultant, Arjawinangun Regional General Hospital, Indonesia Author

DOI:

https://doi.org/10.61841/mjnh1797

Keywords:

Resistant hypertension, prevalence, management

Abstract

Background: Resistant hypertension (RH) increases the morbidity and mortality from stroke and cardiovascular disease in comparison to hypertension without treatment resistance.

Aims: This systematic review is to review the prevalence, risk factor and management of resistant hypertension.

Methods: This study demonstrated compliance with all requirements by means of a comparison with the standards established by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020. Thus, the specialists were able to guarantee that the research was as current as feasible. Publications released between 2014 and 2024 were considered for this search strategy. This was accomplished by utilizing a number of distinct online reference sites, including Pubmed, ScienceDirect, and SagePub. It was determined that reviews, previously published works, and partially completed works would not be included.

Result: In the PubMed database, the results of our search brought up 1032 articles, whereas the results of our search on SAGEPUB brought up 29093 articles, our search on SCIENCE DIRECT brought up 96059 articles. The results of the search conducted for the last year of 2014 yielded a total 556 articles for PubMed, 12517 articles for SAGEPUB and 43884 articles for SCIENCE DIRECT. In the end, we compiled a total of 9 papers, 4 of which came from PubMed, 1 of which came from SAGEPUB and 4 of which came from SCIENCE DIRECT. We included nine research that met the criteria.

Conclusion: In summary, the therapy of lowered heart rate includes improving lifestyle modifications, utilizing longacting thiazide-like diuretics, adding a mineralocorticoid receptor antagonist, and gradually adding antihypertensive drugs with complementary modes of action if blood pressure does not decline.

References

Pimenta E, Calhoun DA. Resistant hypertension: Incidence, prevalence, and prognosis. Vol. 125, Circulation. 2012. p. 1594–6.

Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014 Jun 1;100(11):855–61.

Sarganas G, Neuhauser HK. Untreated, Uncontrolled, and Apparent Resistant Hypertension: Results of the German Health Examination Survey 2008–2011. J Clin Hypertens. 2016 Nov 1;18(11):1146–54.

Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355–61.

Hanus KM, Prejbisz A, Gasowski J, Klocek M, Topor-Madry R, Lesniak W. Relationship between gender and clinical characteristics, associated factors, and hypertension treatment in patients with resistant hypertension. Kardio Pol. 2017;75(5):421–31.

Janković SM, Stojković S, Petrović M, Kostić T, Zdravković M, Radovanović S, et al. Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension. Medicine (United States). 2023 Jun 2;102(22):E33941.

Moura AF, Moura-Neto JA, Rodrigues CIS, Miranda MO, Carvalho TC, Paschoalin Carvalho NP, et al. Resistant hypertension: Prevalence and profile of patients followed in a university ambulatory. SAGE Open Med. 2021;9.

Jin Y, Jacobs L, Baelen M, Thijs L, Renkin J, Hammer F, et al. Rationale and design of the Investigator-Steered Project on intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Press. 2014;23(3):138–46.

Galceran I, Vázquez S, Durán X, Outón S, Pascual J, Oliveras A. Seguridad renal de espironolactona en pacientes con hipertensión arterial resistente. Nefrología. 2020 Jul;40(4):414–20.

Trimarco V, Izzo R, Mone P, Lembo M, Manzi MV, Pacella D, et al. Therapeutic concordance improves blood pressure control in patients with resistant hypertension. Pharmacol Res. 2023 Jan 1;187.

Martial MA, Everitt KA, Martial CS, Day AM, Johnson M, Charles G. Effectiveness of a hypertension management protocol in rural Haitian adults and pregnant women. Dialogues in Health. 2023 Dec 1;3.

Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, et al. Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial. Circulation. 2021 Oct 12;144(15):1212–26.

Ammann EM, O’Brien ES, Milentijevic D, Kharat AA, Talbot DA, Canovatchel W, et al. Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US. Heliyon. 2023 Feb 1;9(2).

Downloads

Published

2024-03-13

How to Cite

Aziz, M. A., Kania, Y. I., Aziz, I., & Sibli. (2024). PREVALENCE, RISK FACTOR, MANAGEMENT AND OUTCOME OF RESISTANT HYPERTENSION: SYSTEMATIC REVIEW. Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425), 10(3), 156-163. https://doi.org/10.61841/mjnh1797

Similar Articles

31-40 of 174

You may also start an advanced similarity search for this article.